Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals During 2016-2018.
The activity of meropenem-vaborbactam and comparators was evaluated against 152 (1.1%) carbapenem-resistant Enterobacterales (CRE) isolates identified among 13,929 Enterobacterales isolates collected from U.S. hospitals during 2016-2018. CRE rates were higher in the Middle Atlantic (3.5%) when compared to other divisions (0.0% for West North Central to 1.4% for West South Central). Among CRE isolates, 134 carried carbapenemase genes that included: 72 bla KPC-3, 51 bla KPC-2, 4 bla NDM-1, 3 bla SME-4, 2 bla VIM-1, 1 bla OXA-232, and 1 bla KPC-4 Meropenem-vaborbactam was active against 95.4% of the CRE isolates and 94.8% of the carbapenem-producing Enterobacterales (CPE) when applying the CLSI breakpoints, respectively. All isolates producing serine carbapenemases were inhibited by meropenem-vaborbactam at ≤8 mg/L. One C. freundii isolate carrying bla KPC-3 had a meropenem-vaborbactam MIC at 8 mg/L and was resistant according to CLSI breakpoints (susceptible applying EUCAST criteria; ≤8 mg/L susceptible) and had disrupted OmpC and OmpF sequences and overexpression of AcrAB-TolC. Carbapenemase-negative CRE (18) were all inhibited by meropenem-vaborbactam at ≤4 mg/L and mIC values against this combination ranged from 0.25 to 4 mg/L. Among 7 isolates carrying metallo-β-lactamases and/or oxacillinases with carbapenemase activity, meropenem-vaborbactam susceptibility was 14.3% and 57.1% when applying CLSI and EUCAST breakpoints, respectively. CRE isolates were resistant to many comparator agents and the most active agents were tigecycline, colistin, and amikacin (63.2% to 96.7% susceptible). Understanding the epidemiology of CRE isolates in U.S. hospitals and their resistance mechanisms among these isolates is important to form guidelines for the treatment of infections caused by these organisms that have high mortality rates.